Vasodilator therapy of dilated cardiomyopathy.
作者信息
Cohn J N
出版信息
Postgrad Med J. 1986 Jun;62(728):599-600. doi: 10.1136/pgmj.62.728.599.
Abstract
Vasoconstriction increases impedance to ventricular ejection and impairs the performance of the dilated myopathic heart. Vasodilator drug therapy by reducing vascular resistance, increasing vascular compliance and increasing vascular capacitance improves cardiac function and relieves the signs and symptoms of congestive heart failure. Earlier intervention in an attempt to alter the natural history of cardiomyopathy should be studied.
摘要
相似文献
1
Vasodilator therapy of dilated cardiomyopathy.
Postgrad Med J. 1986 Jun;62(728):599-600. doi: 10.1136/pgmj.62.728.599.
2
[Impedance rheography in the evaluation of vasodilation treatment of congestive cardiomyopathy].
Kardiol Pol. 1986;29(8):505-14.
3
Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure.
Circulation. 1986 Dec;74(6):1303-8. doi: 10.1161/01.cir.74.6.1303.
4
[The influence of therapy (sympathomimetic amines versus vasodilators) in the indexes of ejection fraction derived from an analysis of Doppler aortic flow].
Rev Port Cardiol. 1998 Jun;17(6):515-22.
5
6
[Therapy of dilated cardiomyopathy with digitalis, diuretics and vasodilators].
Herz. 1985 Jun;10(3):138-42.
7
8
Acute hemodynamic effects of sildenafil in patients with idiopathic dilated cardiomyopathy.
Indian Heart J. 2008 Nov-Dec;60(6):599-601.
9
10
Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
J Cardiovasc Pharmacol. 1989;14 Suppl 2:S23-30.
引用本文的文献
1
Electrical plasticity and cardioprotection in myocardial ischemia--role of selective sodium channel blockers.
Clin Cardiol. 2013 May;36(5):255-61. doi: 10.1002/clc.22113. Epub 2013 Mar 25.
2
Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.
Clin Pharmacokinet. 1989 Feb;16(2):86-9. doi: 10.2165/00003088-198916020-00003.
本文引用的文献
1
Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.
Am J Cardiol. 1982 May;49(7):1659-66. doi: 10.1016/0002-9149(82)90243-0.
2
Regional blood flow response to orthostasis in patients with congestive heart failure.
J Am Coll Cardiol. 1983 Jun;1(6):1391-5. doi: 10.1016/s0735-1097(83)80041-2.
3
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.
N Engl J Med. 1984 Sep 27;311(13):819-23. doi: 10.1056/NEJM198409273111303.
4
Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.
Circulation. 1980 Jul;62(1):35-41. doi: 10.1161/01.cir.62.1.35.
5
Treatment of refractory heart failure with infusion of nitroprusside.
N Engl J Med. 1974 Sep 19;291(12):587-92. doi: 10.1056/NEJM197409192911201.
6
Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance.
Circulation. 1973 Jul;48(1):5-8. doi: 10.1161/01.cir.48.1.5.
7
Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus.
Circulation. 1973 Oct;48(4):684-90. doi: 10.1161/01.cir.48.4.684.
8
Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure.
Circulation. 1978 Nov;58(5):763-70. doi: 10.1161/01.cir.58.5.763.
9
Nitrate therapy for congestive heart failure.
JAMA. 1978 Aug 4;240(5):443-6.
Zotero 插件